Crizotinib, on the other hand, inhibits tumor progression by inhibiting ROS1 or ALK and has been approved for the treatment of advanced lung adenocarcinoma patients with c-ROS1 (ROS1) and anaplastic lymphoma kinase (ALK) gene rearrangements [58]. This evidence concerns the gene ALK and neoplasm.